Cargando…
Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020
Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory N...
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Microbiology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284474/ https://www.ncbi.nlm.nih.gov/pubmed/34060895 http://dx.doi.org/10.1128/AAC.00486-21 |
| _version_ | 1783723399276658688 |
|---|---|
| author | Bhatnagar, Amelia Boyd, Sandra Sabour, Sarah Bodnar, Janine Nazarian, Elizabeth Peinovich, Nadine Wagner, Christine Craft, Bradley Snippes Vagnone, Paula Simpson, Justin Stone, Victoria N. Therrien, Michelle Bateman, Allen Lower, Danielle Huang, Jennifer Y. Gumbis, Stephanie Lonsway, David Lutgring, Joseph D. Karlsson, Maria Brown, Allison C. |
| author_facet | Bhatnagar, Amelia Boyd, Sandra Sabour, Sarah Bodnar, Janine Nazarian, Elizabeth Peinovich, Nadine Wagner, Christine Craft, Bradley Snippes Vagnone, Paula Simpson, Justin Stone, Victoria N. Therrien, Michelle Bateman, Allen Lower, Danielle Huang, Jennifer Y. Gumbis, Stephanie Lonsway, David Lutgring, Joseph D. Karlsson, Maria Brown, Allison C. |
| author_sort | Bhatnagar, Amelia |
| collection | PubMed |
| description | Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution. For 64 clinical isolates tested, the MIC(50) and MIC(90) values of aztreonam-avibactam were 0.5/4 μg/ml and 8/4 μg/ml, respectively. Aztreonam-avibactam displayed potent in vitro activity against the MBL-producing Enterobacterales tested. |
| format | Online Article Text |
| id | pubmed-8284474 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | American Society for Microbiology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82844742022-01-16 Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020 Bhatnagar, Amelia Boyd, Sandra Sabour, Sarah Bodnar, Janine Nazarian, Elizabeth Peinovich, Nadine Wagner, Christine Craft, Bradley Snippes Vagnone, Paula Simpson, Justin Stone, Victoria N. Therrien, Michelle Bateman, Allen Lower, Danielle Huang, Jennifer Y. Gumbis, Stephanie Lonsway, David Lutgring, Joseph D. Karlsson, Maria Brown, Allison C. Antimicrob Agents Chemother Susceptibility Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution. For 64 clinical isolates tested, the MIC(50) and MIC(90) values of aztreonam-avibactam were 0.5/4 μg/ml and 8/4 μg/ml, respectively. Aztreonam-avibactam displayed potent in vitro activity against the MBL-producing Enterobacterales tested. American Society for Microbiology 2021-07-16 /pmc/articles/PMC8284474/ /pubmed/34060895 http://dx.doi.org/10.1128/AAC.00486-21 Text en Copyright © 2021 Bhatnagar et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Susceptibility Bhatnagar, Amelia Boyd, Sandra Sabour, Sarah Bodnar, Janine Nazarian, Elizabeth Peinovich, Nadine Wagner, Christine Craft, Bradley Snippes Vagnone, Paula Simpson, Justin Stone, Victoria N. Therrien, Michelle Bateman, Allen Lower, Danielle Huang, Jennifer Y. Gumbis, Stephanie Lonsway, David Lutgring, Joseph D. Karlsson, Maria Brown, Allison C. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020 |
| title | Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020 |
| title_full | Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020 |
| title_fullStr | Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020 |
| title_full_unstemmed | Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020 |
| title_short | Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020 |
| title_sort | aztreonam-avibactam susceptibility testing program for metallo-beta-lactamase-producing enterobacterales in the antibiotic resistance laboratory network, march 2019 to december 2020 |
| topic | Susceptibility |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284474/ https://www.ncbi.nlm.nih.gov/pubmed/34060895 http://dx.doi.org/10.1128/AAC.00486-21 |
| work_keys_str_mv | AT bhatnagaramelia aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT boydsandra aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT saboursarah aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT bodnarjanine aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT nazarianelizabeth aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT peinovichnadine aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT wagnerchristine aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT craftbradley aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT snippesvagnonepaula aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT simpsonjustin aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT stonevictorian aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT therrienmichelle aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT batemanallen aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT lowerdanielle aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT huangjennifery aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT gumbisstephanie aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT lonswaydavid aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT lutgringjosephd aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT karlssonmaria aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 AT brownallisonc aztreonamavibactamsusceptibilitytestingprogramformetallobetalactamaseproducingenterobacteralesintheantibioticresistancelaboratorynetworkmarch2019todecember2020 |